Answers are grounded in this paper and cite their sources.
To the Editor—We read with interest Witt et al's recent article on the limited durability of protection following acellular pertussis vaccination (DTaP) and we note that disease rates in their study population were highest in 12-year-olds and were dramatically lower in those aged ≥14 years (see Figure 1 [1]). We would like to raise with the authors the possibility that the shift from whole cell pertussis vaccine (DTwP) to DTaP as the primary course vaccine, and particularly the initial vaccine, may have contributed to the age-specific nature of infection in their patient population. Queensland, Australia, which introduced DTaP for the primary course in March 1999, has been experiencing a sustained pertussis outbreak since 2009, with a similar peak in late childhood notifications of disease. We investigated a cohort of children born in 1998, vaccinated during the transition from DTwP to DTaP, and found that receiving a primary course of DTwP was associated with a significantly reduced risk of pertussis when compared to receipt of a DTaP primary course [2]. Receiving DTwP as the first dose in a mixed primary course also appeared to be associated with a similar reduced risk of notification. This differential protection persisted for more than a decade after receipt of the primary course despite most of the children (84%–89%, depending on type of primary course) receiving at least 2 DTaP booster doses (scheduled at 18 months and 4 years of age).
No takes yet. Share an insight, caveat, or question.
Sheridan et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: